Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis
Condition(s) studied
Investigational drug(s) / intervention(s)
Intravenous Ringer's lactate: Intravenous Ringer's lactate
Study summary
This study will explore the efficacies of several practical short-term (peri-procedural) intravenous fluid regimens in the prevention of post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). PEP is the most common serious ERCP-related adverse event (AE), occurring in 5-15% of patients, and associated with significant morbidity, mortality, and healthcare utilization. Given the current lack of data on effectiveness of short-term fluid regimens in PEP prevention to inform practice, the results of the proposed study have the strong potential to impact ERCP practices worldwide, whether positive or negative.
Eligibility
Primary outcome measure(s)
- Serum amylase — 24 hours
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Peter Lougheed Centre | Calgary | Alberta | Recruiting |
More University of Calgary trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06260878 on ClinicalTrials.gov ↗ ← All trials in Canada